Pamuk Omer Nuri, Pamuk Gülsüm Emel, Soysal Teoman, Ongören Seniz, Başlar Zafer, Ferhanoğlu Burhan, Aydin Yildiz, Ulkü Birsen, Aktuğlu Gulten, Akman Nuran
Division of Hematology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey.
South Med J. 2004 Mar;97(3):240-5. doi: 10.1097/01.SMJ.0000053674.03385.B7.
In this study, the clinical characteristics, survival, and prognostic factors of 200 patients diagnosed as having chronic lymphocytic leukemia (CLL) were analyzed.
The medical charts of 200 CLL patients registered to our center between 1984 and 2000 were retrospectively evaluated.
Of all patients, 129 were men and 71 were women (male/female ratio, 1.82). The median age at the time of initial diagnosis was 63 years (range, 38-90 years). Sixty patients were classified as Binet's Stage A, 49 as Stage B, and 91 as Stage C. Sixty-two cases were diagnosed during routine laboratory examinations when they were asymptomatic. Forty-three patients were lost to follow-up, and 157 patients have been followed regularly until the end of the study period. Hemolytic anemia developed in nine (5.7%) patients, second primary cancer in six (3.8%), and Richter's syndrome in two (1.2%). Forty-eight percent of CLL patients were treated immediately after initial diagnosis. The overall response (complete or partial) to first-line and second-line therapies was 61.6% and 54.4%, respectively. The median time of follow-up for patients followed up regularly was 47 months (range, 1-195 months). Sixty-three patients died during the follow-up: the deaths of 39 (62%) of these were attributable to CLL-related causes. The median survival time was 48 months. The 5-year survival rate was 36.5% and the 10-year survival rate was 8%. Stage according to Rai's classification, lymphocyte count, and age showed a significant prognostic effect on survival by univariate analysis. On multivariate analysis, advanced age and lymphocyte count were independent prognostic parameters.
In our study, more asymptomatic CLL patients have been diagnosed in recent years. The survival, especially of our early-stage patients, was shorter than that in other CLL series of Western origin. Rai's staging system was seen to determine prognosis better than Binet's staging system.
本研究分析了200例诊断为慢性淋巴细胞白血病(CLL)患者的临床特征、生存情况及预后因素。
对1984年至2000年间登记在本中心的200例CLL患者的病历进行回顾性评估。
所有患者中,男性129例,女性71例(男/女比例为1.82)。初次诊断时的中位年龄为63岁(范围38 - 90岁)。60例患者被分类为Binet分期A期,49例为B期,91例为C期。62例患者在无症状的常规实验室检查时被诊断。43例患者失访,157例患者被定期随访至研究期结束。9例(5.7%)患者发生溶血性贫血,6例(3.8%)发生第二原发性癌症,2例(1.2%)发生Richter综合征。48%的CLL患者在初次诊断后立即接受治疗。一线和二线治疗的总体缓解率(完全或部分缓解)分别为61.6%和54.4%。定期随访患者的中位随访时间为47个月(范围1 - 195个月)。随访期间63例患者死亡:其中39例(62%)死于CLL相关原因。中位生存时间为48个月。5年生存率为36.5%,10年生存率为8%。单因素分析显示,根据Rai分类的分期、淋巴细胞计数和年龄对生存有显著的预后影响。多因素分析显示,高龄和淋巴细胞计数是独立的预后参数。
在我们的研究中,近年来诊断出更多无症状的CLL患者。我们的患者,尤其是早期患者的生存期,比其他西方来源的CLL系列研究中的生存期短。Rai分期系统比Binet分期系统能更好地确定预后。